Fluidda (Broncholab)
About Fluidda (Broncholab)
Fluidda (Broncholab) is a leading healthcare AI company specializing in Functional Respiratory Imaging (FRI). This proprietary technology integrates high-resolution CT scans with computational fluid dynamics (CFD) and artificial intelligence to create detailed, patient-specific 3D models of lung anatomy and function. For physicians, this means a more precise and comprehensive understanding of respiratory diseases than traditional methods like spirometry, which can often underestimate disease severity due to compensatory mechanisms in the lungs.
Fluidda’s Broncholab platform, cleared by the FDA in 2020 and holding a CE Certificate since 2022, provides quantitative FRI parameters to assist in diagnosing, monitoring disease progression, and optimizing treatment for individual patients. This includes insights into airway geometry, lung volumes, vascular structures, airflow, aerosol deposition patterns, and ventilation/perfusion. The technology helps in phenotyping respiratory diseases like asthma, COPD, cystic fibrosis, ARDS, and ALI, and can be used to evaluate the impact of novel therapeutics. By offering more sensitive outcome parameters, FRI aims to make clinical trials shorter, faster, and more cost-effective, while also facilitating personalized medicine by guiding treatment decisions and assessing the efficacy of inhaled medications.
Beyond clinical trials, Broncholab supports physicians in routine clinical practice by providing reproducible CT values for pulmonary tissue, aiding in diagnosis, follow-up examinations, and detecting subtle changes in lung structure associated with various chronic respiratory and pulmonary vascular diseases. The platform’s ability to visualize and quantify lung abnormalities, even those difficult to discern with the naked eye on a CT scan, allows for earlier intervention and more tailored therapeutic strategies. Fluidda’s technology has also been instrumental in understanding lung abnormalities after COVID-19 infection, by identifying relationships between altered blood flow patterns and breathlessness.
Focus Areas
Business Intelligence
| Technology | Functional Respiratory Imaging (FRI) combining HRCT scans, Computational Fluid Dynamics (CFD), and Artificial Intelligence |
What Physicians Need to Know
Fluidda's Broncholab platform provides physicians with a powerful tool to move beyond the limitations of conventional lung function tests like spirometry. By offering detailed, quantitative, and regional information on lung structure and function from low-dose CT scans, it enables earlier and more accurate diagnosis, precise monitoring of disease progression, and optimization of personalized treatment plans. The ability to visualize ventilation, air trapping, blood flow, and predict drug deposition allows for a deeper understanding of individual patient physiology and response to therapy. This technology can be particularly valuable for identifying patients who may not be responding to conventional treatments or for fine-tuning therapies in complex respiratory conditions. Furthermore, the AI capabilities can assist in predicting disease exacerbations and treatment responses, aiding in proactive patient management.
Fluidda's Broncholab platform processes CT-scan data uploaded to their online platform. The results of the analysis, including various Functional Respiratory Imaging (FRI) parameters, are then sent to the attending physician. This indicates a workflow where CT data is acquired locally and then transmitted to Fluidda for analysis, with the results integrated back into the physician's workflow. The platform is designed to provide quantitative HRCT techniques for clinical practice.
What the Web Says
Fluidda (Broncholab) is a company specializing in Functional Respiratory Imaging (FRI) technology, which uses high-resolution CT scans, computational fluid dynamics, and AI to provide detailed 3D maps of the lungs. The Broncholab platform assists physicians in diagnosing and monitoring respiratory diseases, advancing personalized medicine, and optimizing clinical trials. The company is recognized for its innovative approach to respiratory care, moving beyond traditional spirometry to offer more accurate and regionally specific information about lung health.
Overall: PositiveStrengths
- Provides detailed 3D lung maps from CT scans
- Assists in diagnosis and monitoring of various respiratory diseases
- Helps advance personalized medicine by optimizing treatment
- Reduces the cost and time of clinical trials
- Offers more accurate and regionally relevant information compared to traditional methods
- FDA cleared for clinical use
Limitations
- Limited publicly available reviews from G2, Glassdoor, Capterra, and Reddit specific to Fluidda (Broncholab).
- Information primarily focuses on product capabilities rather than direct user experiences or employer reviews.
- The technology is advanced and may require specialized training for optimal use.
- Potential reliance on high-resolution CT scans may limit accessibility in some settings.
- Specific pricing information is not readily available in the provided search results.
- No direct negative feedback or criticisms were found in the provided search results.
Based on reviews from: AuntMinnie, Fierce Healthcare, Healthcare Tech Outlook, MassDevice, PR Newswire, PubMed Central
Last updated: 2026-10-26
Videos
News, demos, and interviews about Fluidda (Broncholab).
Videos load interactively. If none appear, search YouTube for Fluidda (Broncholab) →
Press & Coverage
Frequently Asked Questions
Related Companies
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]
Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]
CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]
CapsoVision is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (AI) technologies for capsule endoscopy solutions. Their primary goal is to identify abnormalities of the gastrointestinal (GI) tract for diagnostic and screening purposes. [7] Their flagship product, the CapsoCam Plus system, is a single-use capsule endoscope equipped with four cameras, providing […]